Siponimod reduces risk of disability progression by 21%

Mayzent is an oral treatment for relapse remitting MS and active secondary progressive MS.
Post Reply
MSUK
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm
Contact:

Siponimod reduces risk of disability progression by 21%

Post by MSUK »

Scientists who conducted a randomised, double-blind, placebo-controlled, phase III study, evaluating siponimod versus a placebo in patients with secondary progressive multiple sclerosis (SPMS) have managed to reduce the risk of disability progression by 21 per cent, over a three month period...Read more - http://www.ms-uk.org/siponimod-reduces- ... ent-090517
MS-UK - http://www.ms-uk.org/
NHE
Volunteer Moderator
Posts: 5877
Joined: Sat Nov 20, 2004 3:00 pm
Contact:

Re: Siponimod reduces risk of disability progression by 21%

Post by NHE »

MSUK wrote: Tue May 09, 2017 12:15 am Scientists who conducted a randomised, double-blind, placebo-controlled, phase III study, evaluating siponimod versus a placebo in patients with secondary progressive multiple sclerosis (SPMS) have managed to reduce the risk of disability progression by 21 per cent.
That sounds good. However, it's a relative percentage reduction. The actual data plot doesn't look that impressive.


Image
Zyklon
Family Elder
Posts: 369
Joined: Sun Apr 16, 2017 12:45 pm
Location: Turkey

Re: Siponimod reduces risk of disability progression by 21%

Post by Zyklon »

I agree with NHE. Not much improvement and lots of possible side effects.
Pain! You made me a, you made me a believer, believer
Pain! You break me down, you build me up, believer, believer
Pain! Oh let the bullets fly, oh let them rain
My life, my love, my drive, it came from... Pain!
Post Reply
  • Similar Topics
    Replies
    Views
    Last post

Return to “Mayzent (Siponimod)”